Corrigendum to “The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.” Kidney Int. 2021;100:225–237
Gema Ariceta, Bradley P. Dixon, Seong Heon Kim, Gaurav Kapur et autres
es, us, kr (code pays fourni par la source)